Raloxifene

Bezeichnung:Raloxifene

CAS-Nr84449-90-1

Englisch Name:Raloxifene

CBNumberCB1290431

SummenformelC28H27NO4S

Molgewicht473.58

MOL-Datei84449-90-1.mol

Raloxifene physikalisch-chemischer Eigenschaften

Schmelzpunkt	250-253°C
Siedepunkt	728.2±60.0 °C(Predicted)
Dichte	1.289±0.06 g/cm3(Predicted)
storage temp.	Desiccate at +4°C
Löslichkeit	DMSO: 28 mg/mL, soluble
Aggregatzustand	solid
pka	8.83±0.15(Predicted)
Farbe	light yellow
Wasserlöslichkeit	560μg/L at 25℃
LogP	6.09
CAS Datenbank	84449-90-1(CAS DataBase Reference)

Sicherheit

WGK Germany	3
HS Code	29349990
Giftige Stoffe Daten	84449-90-1(Hazardous Substances Data)

Gefahreninformationscode (GHS)

Raloxifene Chemische Eigenschaften,Einsatz,Produktion Methoden

Chemische Eigenschaften
Light-Yellow Solid
Verwenden
A nonsteroidal estrogen receptor mixed agonist/antagonist
Verwenden
Raloxifene is a nonsteroidal, selective estrogen receptor modulator (SERM). Antiosteoporotic.
Indications
Raloxifene (Evista) is a new SERM approved for use in the treatment and prevention of osteoporosis because it has estrogenic activity in bone. Raloxifene is an estrogen antagonist in both breast and endometrial tissues. The estrogenlike properties of raloxifene result in the maintenance of a favorable serum lipid profile (decreased low-density lipoprotein levels with no change in either high-density lipoproteins or triglycerides). Raloxifene is 95% bound to plasma proteins. Absorption of raloxifene is impaired by cholestyramine.
Definition
ChEBI: A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.
Trademarks
Evista (Lilly).
Allgemeine Beschreibung
Raloxifene, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone (Evista), is a benzothiophene derivativethat differs slightly from the triphenylethyleneSERMs. A key structural difference is the carbonyl “hinge”that connects the modified phenolic side chain to the benzothiophenering system. This hinge is the key structural elementthat leads to the differing actions at the ERs.Raloxifene, unlike tamoxifen and toremifene, has antagonistproperties on the endometrium and breast tissue and agonistproperties on bone and the cardiovascular system. The lackof agonist action on endometrial tissue has been suggestedas a reason for the lack of endometrial cancer associatedwith raloxifene use. Raloxifene is approved for the preventionand treatment of osteoporosis in postmenopausalwomen. It has also been investigated for preventing breastcancer in comparison with tamoxifen. Recent studies indicatesthat it has similar effectiveness to tamoxifen, but has apreferable side effect profile.
Biologische Aktivität
Selective estrogen receptor modulator (SERM) that binds to ER α and ER β , and tissue-dependently activates or blocks estrogen-induced transcription. Acts as an antiestrogen in breast and uterine tissue, but displays estrogen agonist activity in bone. In D12 rat hypothalamic cells, inhibits progesterone receptor induction by estrogen with an IC 50 of 1 nM.
Clinical Use
Raloxifene, the first SERM approved for the prevention of osteoporosis in postmenopausal women, acts as an estrogen agonist on receptors in osteoblasts and osteoclasts but as an antagonist at breast and uterine estrogen receptors.

Raloxifene Upstream-Materialien And Downstream Produkte

Raloxifene Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

84449-90-1, Raloxifene Verwandte Suche:

Send Inquriy